Tom D'Amato

Tom D'Amato is currently the Director of Rare Disease Patient Advocacy at Amgen, a role they began after Amgen's acquisition of Horizon in October 2023. Previously, Tom held various positions in the rare disease and orphan drug sectors at Horizon and served as an Obesity and Diabetes Care Specialist at Novo Nordisk. They possess a Bachelor of Science in Psychology from Western Illinois University and have a strong background in patient advocacy, marketing, and training, driven by personal experience with rare conditions and a commitment to positively impacting the healthcare industry.